Monalizumab

DB12824InvestigationalProtein Based Therapies

Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.

Mechanism: Pharmacologically active on NKG2-A/NKG2-B type II integral membrane protein
Curator reviewed
Code names: IPH-2201

Resolves to

Compound

UNII3ZXZ2V0588CAS1228763-95-8

Targets

P26715KLRC1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

24Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Monalizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account